Auspex adds weight as it raises $25m to progress deuterium-modified pipeline
This article was originally published in Scrip
Auspex Pharmaceuticals has raised $25 million in a Series D venture financing round to conduct a pivotal Phase III clinical trial for SD-809, a version of the drug Xenazine (tetrabenazine) for the treatment of chorea associated with Huntington's disease, in which the San Diego-based company believes it has improved pharmacokinetic properties by substituting certain hydrogen atoms with the "heavy" hydrogen isotope deuterium.
You may also be interested in...
Revolution has just one drug in the clinic, but its focus on KRAS excited IPO investors. Also, Deciphera’s $175m offering leads recent follow-ons and Spruce raises $88m in venture capital.
A BLA filing for Zynteglo in beta-thalassemia is expected in the second half of 2020 instead of the first half, but the first commercial patient in the EU will be treated in the first half of this year.
Private Company Edition: While venture capital invested in the industry dropped in 2019, the number of deals rose as investors funded more early-stage VC rounds. Money continues flowing to large deals as well, including $105m for ALX Oncology and $98m for CANbridge.